New York Times Co vs Sana Biotechnology Inc — how do they compare? New York Times Co trades at $75.56 (market cap $12.29B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: New York Times Co is far larger — about 14.1× Sana Biotechnology Inc's market cap, and New York Times Co pays a 1.21% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NYT | SANA | |
|---|---|---|
Market Cap | $12.29B | $873.84M |
Sector | Media | Health |
52-Week High | $85.86 | $5.92 |
52-Week Low | $51.43 | $2.68 |
Enterprise Value | $11.68B | $848.03M |
Dividend Yield | 1.21% | — |
Trailing returns across standard periods
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →